关于我们 公司介绍

About US

关于艾尔普再生医学


南京艾尔普再生医学科技有限公司是国内领先的从事干细胞再生领域的高科技创新型公司,其研发团队运用诺奖级技术,结合企业特有专利,将人体血液中单核细胞重编程到iPSC或进一步高效稳定地分化成心肌细胞。随着企业的快速发展壮大,艾尔普再生医学将陆续展开肝脏、胰腺、神经等相关细胞的再生服务、定制化开发以及再生医学的临床化研究,为国家的产业科研、药物研发、精准医疗以及生物样本库的建设提供更为优质的产品和服务。



Introduction


Help Stem Cell Innovation is a stem cell biotechnology company that is dedicated to develop and provide artificial human somatic cells using a combination of world’s first and state-of-the-art induced pluripotent stem cells (iPSC) and downstream differentiation technologies. Our mission and vision are to revolutionize medical research, drug discovery and development of cellular replacement therapeutics with our range of proprietary cell products, and to further develop them into transplantable organ grafts for cell-based regenerative therapies with superior safety and efficacy.


 

To date Help Stem Cell Innovations is one of the only companies in China to industrially manufacture human cells derived from iPSCs with high quality, purity, and reproducibility and in virtually unlimited quantities. Products and services include, but are not limited to, iPSC reprogramming, NovoCellTM-Cardiomyocytes, NovoCellTM-Cardiac Progenitor Cells, NovoCellTM-Neurons, NovoCellTM-Hepatocytes, NovoCellTM-Astrycytes. The unique technologies in NovoCellTM products and services have been designed to reduce the time, cost, use of animal models and increase human safety to facilitate pharmaceutical discovery and development. Indeed, National Shanghai Center for Drug Safety Evaluation & Research, National Institutes for Food and Drug Control, and Jiangsu Provincial Center for Disease Control and Prevention (CDC) have selected HELP Stem Cell Innovation as the partner of choice to engage in manufacturing human iPSC-derived somatic cells for cardiac toxicity evaluation.


Not only have we achieved this across multiple healthy and diseased donors for the research market, but also we will initiate manufacturing human cells under cGMP conditions—a requirement as these human cellular products move from a tool used in drug discovery into a therapy used in regenerative medicine applications. Peking Union Medical College Hospital, Jiangsu Province Hospital, Shenzhen Precision Medical Research Institute (SZPMRI), and University of Hong Kong are working very closely with HELP Stem Cell Innovations to develop cellular replacement therapy, with the ultimate goal of eventually transplanting healthy iPSC-derived cardiomyocytes into the original patients to improve heart function. Across multiple donors we have ensured the manufacture of high quality, highly pure and reproducible iPSCs, which will launch fully-personalized iPSC-derived cell therapy.


艾尔普再生医学科技有限公司

关注我们的微信